KAS
KROS icon

Kestra Advisory Services’s Keros Therapeutics KROS Stock Holding History

Kestra Advisory Services’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,000
Closed -$20.4K – 3812
2025
Q4 		$20.4K Buy
+1,000
New +$17.5K ﹤0.01% 4506

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Kestra Advisory Services's KROS Position: Q1 2026 in Review

Kestra Advisory Services sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 1,000 shares — an estimated $20.4K sold.

Kestra Advisory Services first reported a position in KROS in Q4 2025 and held it in 1 quarter. The position peaked at $20.4K in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Kestra Advisory Services reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Kestra Advisory Services sold 1,000 Keros Therapeutics shares in Q1 2026, an estimated $20.4K.
  • Kestra Advisory Services first reported a position in Keros Therapeutics in Q4 2025 and held it in 1 quarter.
  • Kestra Advisory Services's Keros Therapeutics position peaked at $20.4K in Q4 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.